糖尿病和血管疾病:新的治疗途径
1Interdisciplinary Research Center "Health Science", Sant'Anna School of Advanced Studies, Pisa, Italy.
Vascular pharmacology
|November 30, 2023
概括
新的糖尿病药物,如GLP1RA和SGLT2抑制剂,显示出对心脏和脏的益处. 双重GIP/GLP1激动剂和芬瑞在2型糖尿病中提供了进一步的治疗血管疾病和糖尿病心肌病的潜力.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 血管疾病是2型糖尿病的重要并发症,需要超越血糖控制的策略.
- 2型糖尿病的综合症性质有助于其血管负担.
- 新出现的证据强调了特定药物类别的心脏脏保护作用.
研究的目的:
- 审查目前和新兴的2型糖尿病药物治疗的心脏和脏潜力.
- 讨论治疗血管并发症的新药,包括糖尿病心肌病.
- 突出糖尿病患者脏保护的机会.
主要方法:
- 审查最近的临床证据和药理学数据.
- 药物类别的分析,包括GLP1受体激动剂和SGLT2抑制剂.
- 探索新的治疗点和药物.
主要成果:
- GLP1受体激动剂和SGLT2抑制剂显示出显著的心脏和脏益处.
- 双GIP和GLP1激动剂显示有望提高疗效.
- 菲内伦成为潜在的脏保护剂.
- 对糖尿病心肌病的药理治疗方法的研究正在进行中.
结论:
- 超出血糖控制的药物治疗对于管理2型糖尿病并发症至关重要.
- GLP1 RAs,SGLT2抑制剂,双GIP/GLP1激动剂和芬是心脏和脏保护的关键进展.
- 针对糖尿病心肌病需要进一步调查和新的治疗方法.
相关概念视频
Diabetes: Management and Pharmacotherapy
289
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
289
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
Glucagon-like Receptor Agonists
329
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
329
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
473
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
473


